Holen Sie sich die Stockscreener-App
3.27
5.49%
-0.19
Handel nachbörslich:
3.27
Schlusskurs vom Vortag:
$3.46
Offen:
$3.38
24-Stunden-Volumen:
1.42M
Relative Volume:
0.61
Marktkapitalisierung:
$554.34M
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-1.1679
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
+2.19%
1M Leistung:
-18.45%
6M Leistung:
-63.67%
1J Leistung:
-68.31%
1-Tages-Spanne:
$3.19
$3.44
1-Wochen-Bereich:
$3.15
$3.525
52-Wochen-Spanne:
$3.02
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
399 BINNEY STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.27 | 554.34M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
HC Wainwright Reiterates “Buy” Rating for Relay Therapeutics (NASDAQ:RLAY) - Defense World
Rhumbline Advisers Acquires 13,532 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
New York State Common Retirement Fund Has $121,000 Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Lowers Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low After Analyst Downgrade - Defense World
Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP - TipRanks
Relay Therapeutics stock target cut to $12 at Citizens JMP - Investing.com
Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments - TipRanks
RLAY stock touches 52-week low at $3.34 amid market challenges - Investing.com
Relay Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relay Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Relay Therapeutics reports Q4 EPS (45c), consensus (55c) - TipRanks
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Manila Times
Relay Therapeutics, Inc. SEC 10-K Report - TradingView
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnin - GuruFocus.com
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings - Yahoo Finance
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - WICZ
Can These Two Major Healthcare Conferences Reveal Relay Therapeutics' Next Big Move? - StockTitan
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday - Defense World
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - The Manila Times
The Potential Rise in the Price of Relay Therapeutics Inc (RLAY) following insiders activity - Knox Daily
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq
Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
This Insider Has Just Sold Shares In Relay Therapeutics - Simply Wall St
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap DownTime to Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 75,324 Shares - MarketBeat
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 140,182 Shares of Stock - MarketBeat
Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock By Investing.com - Investing.com UK
Q2 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down – Should You Sell? - Defense World
Q2 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World
Quarterly Metrics: Quick and Current Ratios for Relay Therapeutics Inc (RLAY) - The Dwinnex
Brokers Issue Forecasts for RLAY Q1 Earnings - Defense World
RLAY’s Market Whiplash: 9.47% YTD Rise, -1.31% Plunge in 30 Days - The InvestChronicle
Analysts Set Expectations for RLAY Q1 Earnings - Armenian Reporter
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News
BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):